Coronavirus medicine in India: Gilead Sciences inks pact with Cipla to sell antiviral drug remdesivir
The EUA is based on available data from two global clinical trials - US National Institute for Allergy and Infectious Diseases` placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19, and Gilead`s global Phase 3 study evaluating remdesivir in patients with severe disease.
Cipla on Wednesday announced it has signed a non-exclusive licensing agreement with US-based Gilead Sciences for the manufacturing and distribution of antiviral drug remdesivir, Photo: